A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).

Chong Guan NgAya Ahmed AbousheishaaSue Yin LowNor Zuraida ZainalKai Shin ThongAzizul Bin AwaluddinTsui Huei LooSapini Binti YacobNik Ruzyanei Nik JaafarNur Iwana Abdul Abdul TaibNurul Ain Binti Mohamad KamalFuad IsmailWan Zamaniah Wi

Published in: Asian Pacific journal of cancer prevention : APJCP (2023)

Vortioxetine seems promising in the management of depression and enhancement of cognitive function and quality of life of cancer patients with Major Depressive Disorder.<br />.

Keyphrases

major depressive disorder
bipolar disorder
papillary thyroid
open label
squamous cell
clinical trial
depressive symptoms
randomized controlled trial
lymph node metastasis
young adults
study protocol
sleep quality
locally advanced
double blind